VALPODAX CR 200

Valpodax CR 200 is formulated with a combination of Sodium Valproate (134 mg) and Valproic Acid (58 mg) in a controlled-release delivery system intended for effective treatment of epilepsy and bipolar disorder. This formulation functions by stabilizing mood and reducing the frequency of seizures through the elevation of gamma-aminobutyric acid (GABA) levels in the brain, which helps to calm excessive neural activity. The controlled-release mechanism is vital as it allows for a steady and gradual release of the medication over time, ensuring consistent therapeutic effects and promoting better adherence to the treatment regimen by patients. Incorporating both compounds in one tablet helps target the underlying neurological issues associated with these conditions, providing a comprehensive approach to management. It is important for patients to follow their healthcare provider’s instructions regarding dosage and administration, as individual responses to treatment may vary. Regular follow-up with a healthcare professional is essential for monitoring the effectiveness of the medication and any potential side effects experienced during therapy. Patients are encouraged to discuss any concerns with their provider to optimize their treatment outcomes. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.